B+
Bull case
30%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
HALO
Halozyme TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$85.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-07
Recent news sentiment (30D)
+0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+62.1
Score
AI commentary
News tone is strongly positive around the Q2 beat, raised guidance, royalty growth, collaboration activity, and reported post-earnings price advance. The $110.19 anchor is above the reported pre-earnings and post-earnings reference prices, suggesting substantial optimism is embedded. Social, options, short-interest, employee, and analyst-revision data are unavailable; this supports positive monitoring rather than a high-conviction buy thesis.
RankAlpha Sentiment Codex - 2026-09-07
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-08-06eventQ2 2026 beat and raised guidance [#SEC-8K-2026-08-06]Medium impact
Halozyme reported record Q2 revenue of $481 million, up 48% year over year, royalty revenue of $308 million, up 50%, and raised full-year 2026 revenue, royalty, EBITDA, and EPS guidance. Stored earnings context also reports revenue and adjusted EPS beats versus estimates [#PR-EARNINGS-2026-08-15].
2026-12-31catalystShare-repurchase execution [#SEC-8K-2026-08-06]Medium impact
Halozyme repurchased approximately $333 million of shares in Q2 and has authorization to repurchase up to $1 billion through December 2028, with at least $400 million expected in 2026. This provides support but is secondary to operating execution.
2026-12-31catalystENHANZE and Hypercon collaboration cadence [#SEC-8K-2026-08-06]High impact
The company reported five new ENHANZE or Hypercon collaboration agreements through July, expanding potential future milestone and royalty opportunities. The key forward monitor is whether additional agreements and partner launches convert into durable royalty growth.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-07 • Updated nightlySource: Internal modelMethodology